Department of Clinical Sciences, Lund University, Lund, Sweden.
BMC Med. 2013 Aug 13;11:180. doi: 10.1186/1741-7015-11-180.
The inflammatory mediator procalcitonin (PCT) has previously been associated with prognosis in myocardial infarction, cancer and sepsis patients. The importance of PCT in the general population is currently unknown. Our aim was to assess the relationship between plasma PCT and the risk of all-cause and cause-specific mortality in apparently healthy individuals with no previous history of cardiovascular disease or cancer.
We performed a prospective, population-based study on 3,322 individuals recruited from the Malmö Diet and Cancer cohort, with a median follow-up time of 16.2 years. Plasma PCT, high-sensitivity C-reactive protein (hsCRP), low-density lipoprotein (LDL), high-density lipoprotein (HDL), triglycerides and cystatin C were measured at baseline and a thorough risk factor assessment was performed for all subjects. The primary end-points of the study were all-cause mortality, cancer mortality and cardiovascular mortality.
Men had higher PCT levels compared to women. In Cox proportional hazard models adjusted for age, sex, hypertension, diabetes, plasma lipids, renal function, body mass index and smoking, baseline PCT was associated with all-cause mortality and cancer mortality in men. The hazard ratio (HR) for men with PCT levels within the highest compared with the lowest quartile was 1.52 (95% confidence interval (CI) 1.07 to 2.16; P = 0.024) for all-cause mortality and 2.37 (95% CI 1.36 to 4.14; P = 0.006) for cancer mortality. Additionally, men with increased plasma PCT were found to be at a higher risk to develop colon cancer (HR per 1 SD increase = 1.49 (95% CI 1.13 to 1.95); P = 0.005). In multivariate Cox regression analyses with mutual adjustments for PCT and hsCRP, PCT was independently associated with cancer death (HR per 1 SD increase = 1.28 (95% CI 1.10 to 1.49); P = 0.001) and hsCRP with cardiovascular death (HR per 1 SD increase = 1.42 (95% CI 1.11 to 1.83); P = 0.006) in men. We found no significant correlations between baseline PCT or hsCRP and incident cancer or cardiovascular death in women.
We disclose for the first time important independent associations between PCT and the risk for all-cause and cancer mortality in apparently healthy men. Our findings warrant further investigation into the mechanisms underlying the relationship between PCT and cancer.
炎症介质降钙素原(PCT)以前与心肌梗死、癌症和败血症患者的预后有关。PCT 在普通人群中的重要性目前尚不清楚。我们的目的是评估在没有心血管疾病或癌症既往史的明显健康个体中,血浆 PCT 与全因和特定原因死亡率的关系。
我们对来自马尔默饮食与癌症队列的 3322 名参与者进行了前瞻性、基于人群的研究,中位随访时间为 16.2 年。在基线时测量了血浆 PCT、高敏 C 反应蛋白(hsCRP)、低密度脂蛋白(LDL)、高密度脂蛋白(HDL)、甘油三酯和胱抑素 C,并对所有受试者进行了全面的危险因素评估。该研究的主要终点为全因死亡率、癌症死亡率和心血管死亡率。
男性的 PCT 水平高于女性。在调整年龄、性别、高血压、糖尿病、血浆脂质、肾功能、体重指数和吸烟的 Cox 比例风险模型中,基线 PCT 与男性的全因死亡率和癌症死亡率相关。与 PCT 水平处于最低四分位组相比,处于最高四分位组的男性的全因死亡率的危险比(HR)为 1.52(95%置信区间(CI)1.07 至 2.16;P = 0.024),癌症死亡率的 HR 为 2.37(95% CI 1.36 至 4.14;P = 0.006)。此外,发现血浆 PCT 升高的男性患结肠癌的风险更高(每增加 1 SD 的 HR = 1.49(95% CI 1.13 至 1.95);P = 0.005)。在针对 PCT 和 hsCRP 进行相互调整的多元 Cox 回归分析中,PCT 与癌症死亡独立相关(每增加 1 SD 的 HR = 1.28(95% CI 1.10 至 1.49);P = 0.001),hsCRP 与心血管死亡相关(每增加 1 SD 的 HR = 1.42(95% CI 1.11 至 1.83);P = 0.006)。我们没有发现女性基线 PCT 或 hsCRP 与癌症或心血管死亡的发生之间存在显著相关性。
我们首次揭示了 PCT 与男性全因和癌症死亡率之间的重要独立关联。我们的研究结果为进一步研究 PCT 与癌症之间关系的机制提供了依据。